Navigation Links
Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
Date:1/3/2009

ALISO VIEJO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that effective December 31, 2008, the company completed its acquisition of Dow Pharmaceutical Sciences, Inc., a privately held dermatology company that specializes in the development of topical products on a proprietary basis, as well as for pharmaceutical and biotechnology companies.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

     Contact:
     Laurie W. Little
     Valeant Pharmaceuticals
     949-461-6002

'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
2. DFB Sells Coria Labs to Valeant Pharmaceuticals
3. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
4. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
5. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
6. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
7. Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations
8. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
9. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
10. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
11. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
(Date:2/23/2017)... SAN DIEGO and SAN FRANCISCO ... , a privately-held regenerative medicine company, and Beyond Type ... living with type 1 diabetes, today announced a grant ... develop a functional cure for type 1 and other ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
Breaking Biology Technology:
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):